SmartCella is a world-leading biotechnology company pioneering the future of targeted therapies by combining first-in-class delivery platforms with cutting-edge cell and gene therapies. The company has three units: SmartWise with the FDA-approved Extroducer, an endovascular device that enables direct tissue or organ infusion to hard-to-reach organs and tumors. SmartCella Solutions creating novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs. Procella with advanced capabilities within stem cell therapy development and cGMP manufacturing inhouse. Procella collaborates with AstraZeneca on a globally licensed cardiac stem cell therapy to repair parts of the heart damaged from a heart attack and has a growing pipeline of stem cell therapies.

SmartCella, founded in 2014, is based in Tullinge, Sweden and has approximately 70 employees, mainly scientists and researchers, with around 20 different nationalities represented.